Timothy Campbell

Company: Bristol Myers Squibb

Job title: Vice President, Immuno-Oncology & Cell Therapy, Early Clinical Development

Seminars:

CD19-directed CAR-T Cell Therapy Manufactured Using a Next-Generation Process, for Severe, Refractory Autoimmune Diseases 11:00 am

• Optimized autologous CAR-T construct • Translational data for B-cell depletion and immune reset in autoimmune patientsRead more

day: Day Two Track B, AM